By Georgi Boyanov BUS 449a: Change Management.  Statistics  History  Medicinal recipes  Vaccines  Innovation  Mergers & Acquisitions.

Slides:



Advertisements
Similar presentations
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
Advertisements

Efficiency, Ethics and Cost in Pharmaceutical Research and Manufacturing Matthew Wirtala Spring 2006.
The Global Burden of Hepatitis C Dr Daniel Lavanchy World Health Organization (WHO) Geneva, Switzerland 3 rd Paris Hepatitis Conference.
Philip J. Ditchfield Manager, Contracts & Licensing GlaxoSmithKline Data Mining and the Pharmaceutical Industry.
An Overview of the Canadian Pharmaceutical Industry
Possible Barriers to Entry “a market served by a single firm” 14 Monopoly.
Big Pharma / THE FACTS New Internationalist 362, November 2003.
January 3, 2003 Kevin Rakin President and Chief Executive Officer Kevin Rakin President and Chief Executive Officer Economic Summit and Outlook 2003.
Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.
The Work of WHO in the South-East Asia Region The Work of WHO in the South-East Asia Region Biennial Report of the Regional Director 1 January
The Pharmaceutical Industry. Industry introduction Opportunity How to get into this industry ?
Pharmaceutical Industry Analysis Nature of the industry: Highly defensive and 15% of U.S. population aged over 60→Highly mature. Main forces are the suppliers,
Industry Rivalry SuppliersBuyers Potential Entry Substitutes Threat of Entry  Smaller cosmetics manufacturers Large firms benefit from economies of scale.
Naming of drugs A marketed drug has three names: a chemical name, a generic name, and a brand name. A chemical name is given when a new chemical entity.
STRATEGIC MANAGEMENT 1 Irina Raynaud Pierre Jean Tessier Nicolas Cabrit Clément Tumoine.
ALAINA ROANE LAB SECTION 2 FEBRUARY 20 TH 2013 GlaxoSmithKline.
Biomedical Technology Unit Treatment for heart disease Heart-lung machine Treatment for cancer Treatment for diabetes Bone marrow transplants.
Introductory course on Competition and Regulation Pál Belényesi University of Verona October 2006.
Achieving Self Reliance in Vaccine Production in The Islamic World 1st Meeting of Vaccine Manufacturers Group Jeddah, KSA, 25 – 26 June 2014 ISLAMIC DEVELOPMENT.
Eisai Inc. Prep Session, March 1, 2007 Elena Arvanitis Site visit, March 2, 2007 Seminar topic Investing in the Rx Industry – Mixing Medicine with Business.
Overview Industry Overview Impacted Industries Science Business Issues Examples Where do you fit? Getting Involved Websites Other Resources.
Nestlé Acquisition of Gerber Jeff Hsu Joe Orvidas.
An Alternative to Pharmaceutical Patents Christian Engström Vice Chairman, The Swedish Pirate Party.
International Public Health Globalization and Disease in history Black death in 14th century Europe Smallpox in the Americas Great Influenza of 1918.
Douglas Pharmaceuticals Ltd
Pfizer’s Commitment to the Advance Market Commitment (AMC)
The Monitor 100 tm … a 20 year History 1 Chart 1: Outstanding Assets Financed ($ billions) Total Monitor 100.
First Annual Global Employers’ Summit Bahrain 2015 Trade, Jobs and Growth 7 TH OCTOBER 2015 BLAISE MATTHEY, GENERAL MANAGER.
“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.
Drug Use : An Overview Page 7 notes. Page 7 Definitions and Overview Drug use affects: Every age group Every racial/ethnic group Every SES (socio-economic.
…Making Medicines More Affordable… Robert A. Armitage, Senior Vice President and General Counsel May 7, 2010 Creating the Best Medicines for Patients…
Anti-Competitive Behavior Monopolies, Barriers to Entry and How to Construct Them.
Traditional Medicine Vs Modern Medicine s
Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals.
Sustainable Companies for the 21st Century Evolution of the Components of Sustainability for GlaxoSmithKline Dr. James Hagan Vice President Corporate Environment,
Precision Medicine Market share of over 30% dominated by Oncology applications
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Genitourinary Drugs Market Share, Segmentation, Report 2024.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Precision Medicine Market share to hit $87.7bn by 2023
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Worldwide Cancer Biological Therapy market forecasts on regional growth, industry players and more
© Coherent market Insights. All Rights Reserved BIOSIMILAR PIPELINE ANALYSIS MARKET Global Industry Insights, Trends, Outlook, and Opportunity Analysis,
Vaccine Company Perspective Dr Gaurav Gupta, ZYDUS CADILA
Research & development
Road to Medical Innovation & Access: from a rear-view mirror
27 years of responding to AIDS
UNITAID Overview Joint Consultation on Seasonal Malaria Chemoprevention Ouagadougou, Burkina Faso, February 2017.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Breast Cancer Therapeutics.
20 Organization Size.
27 years of responding to AIDS
Copyright 2005 Prentice- Hall, Inc.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Genitourinary Drugs Market.
Global Vaccines Market to witness growth of 9% CAGR from 2017 to 2024
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Preventive and Therapeutic.
Vaccines Market to grow at 9% CAGR from 2017 to 2024
Precision Medicine Market to witness more than 10.5% CAGR from 2017 to 2024
Top 20 largest R&D spenders
A Decade of Data Scott Billman, Biogen
An Increasing Demand for Prescription Drugs Drives Profitability
27 years of responding to AIDS
Think Locally, Act Globally
Medicine in third world countries
دانشگاه شهیدرجایی تهران
Vaccines.
Advances in Understanding: (Genetics and Lifestyle)
Funding gaps to realize the Global Plan to End TB
تعهدات مشتری در کنوانسیون بیع بین المللی
Vaccines.
بسمه تعالی کارگاه ارزشیابی پیشرفت تحصیلی
Achieving Sustainable API Production in Africa
The Big Picture: Why is FDI becoming more important?
Expert Speak: How Pharma Companies Can Grow Their Business?
Presentation transcript:

by Georgi Boyanov BUS 449a: Change Management

 Statistics  History  Medicinal recipes  Vaccines  Innovation  Mergers & Acquisitions

 Revenues: $980 billion annually;  The Big Three: ◦ Novartis (Swiss) - $46 billion revenue, $9.3 billion R&D ◦ Pfizer (US) - $44.5 billion revenue, $7.1 billion R&D ◦ Roche (Swiss) - $40 billion revenue, $8.6 billion R&D  US Market – 40% of the global market;  Development of a new drug: ◦ From research to market – years; ◦ Costs between $1-11 billion, average is $4 billion

 Mid 19 th century – from botanical remedies to manufacturing

 Beginning of 20 th century: ◦ Regulation – from independent small scale manufacturers to controlled premarket approvals  Recipes:

 Beginning of the 20 th century: ◦ Pneumonia ◦ Tuberculosis ◦ Infections  Penicillin  Vaccines – prevention rather than control ◦ Polio ◦ Tuberculosis ◦ Measles

 The change towards “Personalized Medicine”: ◦ The right treatment for the right person at the right time…  Vertical integration  Supporting regulations

Thank you for your attention!